News Seelos Therapeutics, Inc.

Stocks

SEELQ

US81577F4063

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 12:25:32 2026-06-01 EDT			5-day change	1st Jan Change
0.000100 ^USD	+9,900.00%		-.--%	-

12-28	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-10-21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI

All News

Mentions Relevance

12-28	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-10-21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI
25-10-14	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-08-15	Bidding Procedure Approved for Seelos Therapeutics, Inc.	CI
25-04-30	Motion for Asset Sale Filed by Seelos Therapeutics, Inc.	CI
25-04-29	Motion for Case Conversion or Dismissal Filed for Seelos Therapeutics, Inc.	CI
24-11-22	Seelos Therapeutics : Late Filing Notice Form NT 10 Q	PU
24-11-15	Seelos Therapeutics, Inc. Filed for Bankruptcy	CI
24-10-24	Seelos Therapeutics : Announces Second Postponement of its Annual Meeting of Stockholders Form 8 K	PU
24-10-24	Seelos Announces Second Postponement of its Annual Meeting of Stockholders	PR
24-10-17	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index	CI
24-10-15	Seelos Therapeutics : Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over the Counter Market Form 8 K	PU
24-10-15	Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market	PR
24-10-14	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index	CI
24-10-07	Seelos Therapeutics : Material Event Form 8 K	PU
24-09-26	Seelos Therapeutics : Announces Postponement of its Annual Meeting of Stockholders Form 8 K	PU
24-09-26	Seelos Announces Postponement of its Annual Meeting of Stockholders	PR
24-09-25	Seelos Therapeutics Announces 1-for-16 Reverse Stock Split	PR
24-09-24	Seelos Therapeutics, Inc. Announces the Signing of A Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity	CI
24-09-24	Seelos Therapeutics Says Ketamine-Based Therapy Chosen for Government PTSD Study	MT
24-09-24	Seelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD	PR
24-08-15	Seelos: Q2 Earnings Snapshot	AQ
24-08-14	Seelos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-05-16	Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	PR
24-05-15	Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding	CI